Short Interest Update on Intrexon Corporation (XON)

Intrexon Corporation (XON) : The bears are holding on to their shorts in Accenture Plc with 9 more days remaining for them to cover their positions. The bearish positions have increased from 16,690,765 on Jul 29, 2016, to 17,008,586, on August 15, 2016. Daily, 1,877,612 shares are traded, which shows the high interest of the traders in the stock. The net addition of short open interest is 317,821 shares, which is an increase of just 1.9%. The total short interest of 31.3% of the float indicates that there arent many bears on this stock at the current prices. The short interest information was released on Wednesday Aug 24th after the market close.

Intrexon Corporation (NYSE:XON): The stock opened at $29.31 on Wednesday but the bulls could not build on the opening and the stock topped out at $29.71 for the day. The stock traded down to $26.20 during the day, due to lack of any buying support eventually closed down at $26.29 with a loss of -10.18% for the day. The stock had closed at $29.27 on the previous day. The total traded volume was 2,998,488 shares.


In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Intrexon Corp, Kirk Randal J, had purchased 124,475 shares in a transaction dated on December 11, 2015. The transaction was executed at $29.84 per share with total amount equaling $3,714,334.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.